Feed aggregator

New drug prevents flu-related inflammation and lung damage

World Pharma News - Wed, 04/10/2024 - 10:00
Infection with the influenza virus leads to lung injury through inflammation over-activation that causes collateral damage to cells required for breathing. Such damage can be life-threatening, but scientists have a new preventative treatment. A team from St. Jude Children's Research Hospital, University of Houston, Tufts University School of Medicine and Fox Chase Cancer Center created a drug that can prevent flu-induced lung injury. In a mouse model, the drug achieves a novel balance between shutting down runaway inflammation and allowing the immune system to stop the virus.

Swapping red meat for herring/sardines could save up to 750,000 lives/year in 2050

World Pharma News - Tue, 04/09/2024 - 10:00
Swapping red meat for 'forage fish', such as herring, sardines, and anchovies, could save up to 750,000 lives a year in 2050 and significantly reduce the prevalence of disability as a result of diet-related disease, suggests a data analysis published in the open access journal BMJ Global Health.

Adopting this type of diet would be especially helpful for low and middle income countries, where these fish are cheap and plentiful, and where the toll taken by heart disease, in particular, is high, say the researchers.

Does cannabis use affect cognitive decline?

World Pharma News - Mon, 04/08/2024 - 10:00
A new study by Upstate Medical University researchers shows that recreational cannabis use may offer protection against cognitive decline.

The study, done by Master of Public Health (MPH) student Zhi Chen and Professor Roger Wong, Ph.D., MPH, MSW, analyzed a large data set from the CDC and found that compared to non-users, non-medical cannabis use, such as for recreational purposes, was significantly associated with 96 percent decreased odds of subjective cognitive decline (SCD).

Novel biological mechanism discovered that could lead to new treatments for neurological disorders, cancers

World Pharma News - Fri, 04/05/2024 - 10:00
The lab of Yongchao C. Ma, PhD, at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago discovered a fundamental biological mechanism that could lead to new treatments for neurological diseases, such as spinal muscular atrophy (SMA) and autism, as well as different cancers. The study was published in the journal Human Molecular Genetics.

Dr. Ma's team found that chemical modification of RNA (called RNA methylation) regulates mitochondrial function.

New study paves the way for precision drugs to treat blood cancers

World Pharma News - Thu, 04/04/2024 - 10:00
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain.

Moderna Moves Cambridge Employees Into New Headquarters

Biospace news - Thu, 04/04/2024 - 02:00
Moderna Moves Cambridge Employees Into New Headquarters 4/4/2024

How to Manage Your Manager: Tips for Managing Up

Biospace news - Thu, 04/04/2024 - 02:00
How to Manage Your Manager: Tips for Managing Up 4/4/2024

The Top 11 Companies Hiring in Biopharma Now

Biospace news - Thu, 04/04/2024 - 02:00
The Top 11 Companies Hiring in Biopharma Now 4/4/2024

Johns Hopkins investigators develop novel treatment for T-cell leukemias and lymphomas

World Pharma News - Wed, 04/03/2024 - 10:00
A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

The therapy, an antibody-drug conjugate (ADC), combines an antibody that targets a protein called TRBC1 expressed on the surface of T-cell cancers with an anti-cancer drug, called SG3249.

Scientists link certain gut bacteria to lower heart disease risk

World Pharma News - Tue, 04/02/2024 - 10:00
Changes in the gut microbiome have been implicated in a range of diseases including type 2 diabetes, obesity, and inflammatory bowel disease. Now, a team of researchers at the Broad Institute of MIT and Harvard along with Massachusetts General Hospital has found that microbes in the gut may affect cardiovascular disease as well. In a study published in Cell, the team has identified specific species of bacteria that consume cholesterol in the gut and may help lower cholesterol and heart disease risk in people.

Mayo Clinic scientists pioneer immunotherapy technique for autoimmune diseases

World Pharma News - Mon, 04/01/2024 - 10:00
Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.

The new technique, detailed in a preclinical study published in Nature Biomedical Engineering, involves combining chimeric antigen receptors (CAR) with mesenchymal stromal cells (MSC), resulting in engineered stem cells known as CAR-MSCs.

WuXi AppTec Shared Client IP with Beijing, Say US Intelligence Officials: Reuters

Biospace news - Fri, 03/29/2024 - 02:00
WuXi AppTec Shared Client IP with Beijing, Say US Intelligence Officials: Reuters 3/29/2024

BMS’ Zeposia Fails to Meet Primary Endpoint in Phase III Crohn’s Trial

Biospace news - Fri, 03/29/2024 - 02:00
BMS’ Zeposia Fails to Meet Primary Endpoint in Phase III Crohn’s Trial 3/29/2024

Gilead Wins Label Expansion for Vemlidy to Treat Hepatitis B Virus in Kids

Biospace news - Fri, 03/29/2024 - 02:00
Gilead Wins Label Expansion for Vemlidy to Treat Hepatitis B Virus in Kids 3/29/2024

FDA Extends Review Period for Applied Therapeutics’ Govorestat by Three Months

Biospace news - Fri, 03/29/2024 - 02:00
FDA Extends Review Period for Applied Therapeutics’ Govorestat by Three Months 3/29/2024

The IRA, Medicare and the High Costs of GLP-1 Drugs Like Wegovy

Biospace news - Fri, 03/29/2024 - 02:00
The IRA, Medicare and the High Costs of GLP-1 Drugs Like Wegovy 3/29/2024

What Lonza’s $1.2B Buy of Roche Biologics Plant Means for CDMO Market

Biospace news - Fri, 03/29/2024 - 02:00
What Lonza’s $1.2B Buy of Roche Biologics Plant Means for CDMO Market 3/29/2024

Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot

Biospace news - Fri, 03/29/2024 - 02:00
Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot 3/29/2024

Gamida Restructures Under Ownership of Highbridge Capital Management

Biospace news - Fri, 03/29/2024 - 02:00
Gamida Restructures Under Ownership of Highbridge Capital Management 3/29/2024

Advancing drug discovery with AI: introducing the KEDD framework

World Pharma News - Thu, 03/28/2024 - 11:00
A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field of drug discovery. This innovative framework adeptly integrates structured and unstructured knowledge, enhancing the AI-driven exploration of molecular dynamics and interactions.